Introduction

The emergence of imaging genetics to investigate the impact of individual genetic variation on brain function was presaged by the methodological application of functional magnetic resonance imaging (fMRI) to schizophrenia research. In 1996, it was first proposed that functional magnetic resonance imaging, because of its technical advantages over nuclear imaging techniques related to enhanced spatial and temporal resolution and noninvasiveness, would enable individual brain phenotype characterization for genetic association studies.1 Further, two seminal

We review critical trends in imaging genetics as applied to schizophrenia research, and then discuss some future directions of the field. A plethora of imaging genetics studies have investigated the impact of genetic variation on brain function, since the paradigm of a neuroimaging intermediate phenotype for schizophrenia first emerged. It was initially posited that the effects of schizophrenia susceptibility genes would be more penetrant at the level of biologically based neuroimaging intermediate phenotypes than at the level of a complex and phenotypically heterogeneous psychiatric syndrome. The results of many studies support this assumption, most of which show single genetic variants to be associated with changes in activity of localized brain regions, as determined by select cognitive controlled tasks. From these basic studies, functional neuroimaging analysis of intermediate phenotypes has progressed to more complex and realistic models of brain dysfunction, incorporating models of functional and effective connectivity, including the modalities of psycho-physiological interaction, dynamic causal modeling, and graph theory metrics. The genetic association approaches applied to imaging genetics have also progressed to more sophisticated multivariate effects, including incorporation of two-way and three-way epistatic interactions, and most recently polygenic risk models. Imaging genetics is a unique and powerful strategy for understanding the neural mechanisms of genetic risk for complex CNS disorders at the human brain level.
reports of gene variation associated with altered brain activity served as an initial proof-of-principle and heralded the onset of imaging genetics. In 2000, variation in the ApoE genotype was reported to be associated with altered activity in brain regions affected by Alzheimer’s disease during a memory task (in hippocampus, parietal, and prefrontal regions) and in 2001, a functional variation in the catechol-O-methyltransferase (COMT) genotype was reported to be associated with altered prefrontal activity during a working memory task, setting the stage for subsequent investigations of the impact of individual genetic variation on brain activity, as detectable by fMRI. Concurrent with the methodological advances of imaging genetics was the conceptual advance of appreciating the neuroimaging intermediate phenotype as a manifestation of biological risk for a psychiatric syndrome. It was reasoned that susceptibility genes for schizophrenia do not directly encode for the clinical syndrome with which they are associated, that is, they do not directly encode for psychopathology, such as first-rank symptoms of hallucinations or delusions; rather susceptibility genes for schizophrenia are affecting basic biology—the development of brain cells and neural systems that underlie the expression of the clinical symptoms of the syndrome. It was posited that the effects of susceptibility genes would be more penetrant, i.e., “closer to the gene,” at the level of biologically based neuroimaging intermediate phenomena rather than at the level of a complex and phenotypically heterogeneous psychiatric syndrome. Neuroimaging intermediate phenotypes, akin to cognitive or electrophysiological intermediate phenotypes, could therefore be used to enhance the potential to link genetic variation to a complex psychiatric disorder, such as schizophrenia.

Hundreds of published articles have ensued, describing studies to investigate the association of genetic variation with brain activity as pertinent to schizophrenia and other CNS disorders. We currently review several critical trends in the evolution of the field of imaging genetics as applied to schizophrenia research. We then discuss where we are poised to go next: innovations in imaging analysis and genetics analysis, effective connectivity modeling, and polygenic risk models are on the peak of the next wave of imaging genetics.

**The neuroimaging intermediate phenotype**

The neuroimaging intermediate phenotype is conceptually analogous to an intermediate phenotype for common complex medical disorders. It is logical to assume that genes would show stronger associations with the biological substrates contributing to risk of a disorder, with measurable quantitative traits along a pathophysiologic causal pathway, intermediate to the end complex syndrome. Intermediate phenotypes in other realms of medicine include lipid level as an intermediate phenotype for heart disease, sodium homeostasis as an intermediate phenotype for hypertension, and body mass index as an intermediate phenotype for diabetes. We favor the term “intermediate phenotype” over the more popular term “endophenotype,” though the two terms are essentially interchangeable. The term “endophenotype” (which was introduced into psychiatric genetics in the 1970s) initially referred to a trait that is “internal” that may be discoverable by a “biochemical test or microscopic examination,” but is not external or overtly manifest. Also, the term “endophenotype” does not emphasize the concept of intermediacy in pathogenicity. Criteria for the establishment of a neuroimaging-based intermediate phenotype for schizophrenia, as in other fields of medicine, are that the intermediate phenotype: (i) is heritable; (ii) is found with increased frequency in healthy relatives of ill probands; (iii) exists temporally before the onset of the clinical illness in the pathophysiological pathway to the emergence of the clinical syndrome. As expounded in a review by Tan et al, evidence for each of these criteria has accumulated for the syndrome of schizophrenia, with cognitive dysfunction often integral and assayable at the brain level by task-based neuroimaging intermediate phenotypes. Each of these criteria are consistent with the assumption that the intermediate phenotype is genetically and biologically less complex than the clinical syndrome, and that genes showing association at the syndromal level will show greater effect sizes (penetrance) on variation in intermediate phenotypes.

According to the neuroimaging genetics paradigm, to simply demonstrate that a susceptibility gene for schizophrenia impacts brain function is a necessary but not sufficient biological proof of a mechanism of susceptibility. This is because many, if not most, genes expressed in the brain, are apt to have a brain effect of some sort. A *sine qua non* of this proof is to show that the physiological intermediate phenotype associated with a susceptibility gene for schizophrenia is itself linked to illness risk. To make this link, it is necessary to demonstrate that the physiological intermediate phenotype is a characteristic
of individuals who are at increased genetic risk but do not manifest the clinical syndrome. The ideal samples in which to demonstrate this are unaffected relatives, e.g., co-twins, siblings. This has been done for a number of brain-associated intermediate phenotypes related to increased risk for schizophrenia, including cognitive dysfunctions and neuroimaging phenotypes.9-14 Thus, the study of healthy relatives as a target population is critical for establishing the link between genetic association with clinical risk, and genetic association with biological risk. Having identified a neuroimaging phenotype related to increased genetic risk for illness, investigators can ask the question of whether genetic variation in a gene of interest maps onto the specific phenotype, as an indication of its putative neural mechanism of risk. The question arises of which population to choose to conduct this test. Neuroimaging studies of only affected subjects is confounded by illness-associated epiphenomena that are difficult to control, including smoking history, medical comorbidities, chronic illness burden, or prolonged neuroleptic exposure. This makes results in patient samples difficult to interpret, as the associations may reflect an interaction of the gene with any of these epiphenomena. Instead, the imaging genetics paradigm to test a specific gene-association hypothesis, i.e., the association of variation in a putative susceptibility gene and brain function linked to increased genetic risk, is best performed in healthy subjects. Healthy individuals possess common at-risk genotypes, but are not themselves symptomatic or clinically ill, thereby reducing the effect of confounding variables. This approach isolates the simple biologic effect of the genetic variation on brain function.

Some neuroimaging caveats

In contrast to functional neuroimaging, structural imaging has not yielded robust intermediate phenotypes for schizophrenia, although a myriad of structural MRI studies have revealed whole brain and region-specific volume and other differences between patients with schizophrenia and controls.15-17 As discussed elsewhere,18 variation in structural MRI measurements may be

---

**Figure 1.** The brain imaging intermediate phenotype concept.
attributable to artifacts other than the disease itself, physiological alterations in brain tissue (e.g., tissue perfusion, body fat, or water content),\textsuperscript{19} or differences in image acquisition and analysis techniques. Alterations in body weight,\textsuperscript{20} alcohol intake,\textsuperscript{21} steroid administration and hormonal status,\textsuperscript{22} can also change brain volume. Of critical importance in evaluating patients with chronic schizophrenia, medication can alter brain volume, sometimes rapidly: lithium carbonate reportedly increased cortical gray matter volume by 3\% in patients with bipolar affective disorder after 4 weeks of treatment,\textsuperscript{23} and multiple studies have reported basal ganglia volume change with neuroleptics over a duration of time intervals, including longitudinal studies of first-episode patients.\textsuperscript{24,25} Furthermore, there has been a lack of reliability in reports of the heritability of brain structures, with volume reductions in unaffected siblings inconsistent across brain regions and different studies, and not consistently overlapping with genetic liability to schizophrenia, decreasing the utility of structural volumetric indices as intermediate phenotypes.\textsuperscript{26,27} Increasingly, a growing number of research groups have used resting-state fMRI to map brain networks as well as diffusion tensor imaging (DTI) to investigate white matter abnormalities in patients with schizophrenia compared with controls. These modalities and investigations, however, are beyond the current focus of imaging genetics in the present review, but have been reviewed in depth elsewhere.\textsuperscript{28-32} We would emphasize two caveats with respect to these approaches: (i) the analysis of resting fMRI patterns is very sensitive to variation in head motion and to the mental state of the subject, making problematic comparisons between ill and well samples\textsuperscript{33}; and (ii) DTI is based on highly derived data which are highly susceptible to many artifacts and biological events unrelated to white matter structure, rendering interpretation of the results also highly problematic.\textsuperscript{34}

In considering activation-based fMRI as applied to schizophrenia research there are methodological assumptions and limitations to recognize—the same limitations of fMRI in general—in its application to elucidating other CNS disorders or any cognitive function.\textsuperscript{35} Firstly, brain mapping is predicated on the assumption of a modular organization of the brain, that there is a functional segregation with specialized and spatially separated modules, with interconnection of the entities and functional integration by distributed systems. Only according to this assumption can fMRI be then employed to reveal hierarchical decompositions of brain functional units. Another assumption is that a brain structure can be conceptualized as an information processing entity, with an input, a local processing capacity, and an output. Yet, the traditional cortical input-elaboration-output scheme, a correlate of the perception-cognition-action tripartite model, may be an oversimplification. In contributing to neuronal output, a change in balance between excitation and inhibition may predominate over a more straightforward hierarchical connectivity feedforward and feedback model.\textsuperscript{36,37} Further, as for all hemodynamic-based modalities, fMRI measures a surrogate signal of brain function, but then justifies the assignment of a functional role to an “active” area, presuming the change in signal results from the change of activity of a neuronal population. Also, the blood oxygen level-dependent (BOLD) signal reflects neuronal mass activity that may limit its neurobiological inferences, even while being advantageous in some global instances. According to one estimate there are about 90 to 100 000 neurons under 1 mm\(^2\) of cortical surface,\textsuperscript{38} or as another metric, an unfiltered fMRI voxel contains 5.5 million neurons, and 2.2-5.5x10\(^{10}\) synapses, in contrast to traditional microelectrode recordings. Lastly, for task-based fMRI neuroimaging studies, using a block design, a subtraction method is required to compare a task state with an investigator-designed control state, requiring a detailed task analysis to determine subtraction components and their interactions. Despite the above select critiques, fMRI remains the best tool at present for gaining insight into brain function, as many of these considerations are rendered relatively nonsystematic because of the principle of every subject serving as his/her own control and the comparison of signals from one state to another. Thus, fMRI activation approaches allow for the ability to test discrete hypotheses about definable brain functions, especially the impact of genetic variation on these functions.

**Identifying gene associations with regions of brain activation and neural circuits**

Early studies mapped single genes selected based on a measure of candidacy, to an area of brain activation. Examples in addition to \textit{COMT} mentioned above,
include the association of a GRM3 variant with inefficient prefrontal function during a working memory task, or the association of the short (S) variant in a variable repeat sequence in the promoter of the serotonin transporter gene, 5-HTTLPR, with altered amygdala activity during an emotionally evocative task. Illustrative of genetic vulnerability maps of brain function based on imaging genetics approaches, Rasetti et al reviewed neuroimaging intermediate phenotypes of schizophrenia and the gene variants associated with them, catalogued by cognitive task. For example, working memory tasks have revealed abnormal engagement of: dorsolateral prefrontal cortex associated with CACNA1C, COMT, GAD1, GRM3, DRD2, KCNH2, MTHFR, and RGS4; ventrolateral prefrontal cortex associated with COMT, PRODH, and RGS4; thalamus and hippocampus associated with NRG1, DAOA/G72, and DISCI; and parietal lobe associated with PRODH. Cognitive control tasks (designed to challenge executive function of goal-directed behavior in the presence of conflict) have identified abnormal engagement of the anterior cingulate cortex associated with COMT, DRD2, and MAOA; of the dorsolateral prefrontal cortex (DLPFC) associated with DTNBPI, DRD2, MAOA, and COMT; and of the parietal cortex associated with DRD2, and MAOA. Memory encoding tasks recently identified abnormal engagement of hippocampus-parahippocampus region and association of the hippocampus with BDNF, COMT, DISCI, GRM3, and KCNH2. It is worthwhile to note that most association studies of brain function have used single gene variants and risk haplotypes emerging from linkage studies and more recently genome wide association studies, with differing levels of genetic evidence for each candidate gene, though there has been no systematic approach to date to selecting genes for imaging genetics studies. Imaging genetics approaches have progressed to associating gene variants with multiple regions of activation, with disease-relevant risk circuits and putative distributed functional networks, rather than isolated, single regions. After all, brain information processing does not occur as discrete activation “blobs,” but as activity across distributed neural systems and circuits. Thus, circuit-based phenotypes would be expected to have greater fidelity in showing genetic association at the level of brain function, since in principle, the more realistic the phenotype, the stronger the genetic association. As schizophrenia is an emergent property of neural system function, not isolatable to a singular brain region or localized regional defect, but likely attributable to network-based neurointegrative deficits, neuroimaging and intermediate phenotyping strategies have progressed to better understand distributed networks associated with increased genetic risk. To identify a functional network or interregional coupling, functional connectivity between spatially remote regions is inferred based on temporal coherence, by identifying regions of coactivation. Statistical analyses used for functional connectivity include mapping based on seed voxel correlations, principal component analysis, independent component analysis, and partial least squares methods.

The functional connectivity literature within schizophrenia research has largely focused on PFC connectivity, especially the DLPFC and anterior cingulate, and DLPFC interaction with the medial temporal lobe, specifically the hippocampal formation (HF), and interaction with the DLPFC-thalamus. For the DLPFC, abnormal connectivity has been identified in multiple studies in patients with schizophrenia and in high-risk subjects and various genetic associations have been established with this putative circuit, during working memory tasks. For example during the n-back working memory task, COMT-associated activation changes mapped onto a prefrontal-parietal-striatal circuit, involving the DLPFC, ventrolateral prefrontal cortex (VLPC), the posterior parietal regions, and the striatum. A PRODH schizophrenia risk haplotype was associated with increased striatal-frontal functional connectivity, while the protective haplotype was associated with decreased striatal-frontal functional connectivity. A 7 single-nucleotide polymorphism (SNP) haplotype of PPP1R1B (encoding DARPP-32) was associated with functional coupling and increased activation of the striatum and prefrontal cortex. An RGS4 variant was found to impact frontoparietal and frontotemporal coupling. A CACNA1C risk SNP was associated with decreased prefrontal-hippocampal connectivity. While some functional connectivity studies have employed a classic intermediate phenotype strategy, testing for regions of correlation in affected subjects as well as unaffected relatives, many studies appear to query the association of risk susceptibility gene variants with correlated regions in healthy subjects or affected patients alone, with the putative neural circuit then pending validation as an intermediate phenotype.
Psycho-physiological interaction (PPI) analysis is an alternative approach to estimating connectivity, and measures a regionally specific response in terms of an interaction between a cognitive (or sensorimotor) process and activity in another part of the brain. The supposition is that the remote region is either the source of afferents that confer functional specificity on the target region or is activated by efferents that are specifically active during the task. PPI, therefore, allows for the exploration of the effects of an independent variable (eg, genotype) on task-related differences in interregional connectivity.\(^5\) As a specific example, combining information about activity in the parietal region, mediating attention to a particular stimulus, and information about the stimulus, PPI aims to identify regions that respond to that stimulus when, and only when, activity in the parietal region is high. If such an interaction exists, then one might infer that the parietal area is modulating responses to the stimulus for which the area is selective. While this approach offers a deeper functional probe of network activity than simple time series correlation analyses, it is still based on a correlation of activity and not on a directional model of activity in one region influencing activity in another.

In one study, during the N back task, DLPFC-HF coupling was identified in both patients with schizophrenia and their unaffected relatives, and associated with a \(ZNF804A\) risk allele, using seeded connectivity as well as PPI approaches.\(^6\) PPI analysis showed a reduction in task load–related modulation of coupling between the right DLPFC and bilateral HF, in patients and siblings, compared with controls. Further, subjects homozygous for the risk-associated allele of \(ZNF804A\) showed a disruption in task-related modulation of right DLPFC–left HF coupling in the PPI analysis. The seeded connectivity analysis showed similar results to the PPI analysis in DLPFC-HF coupling.

Overall then, functional connectivity analysis offers some insight into correlation between different brain regions, but is limited in that it does not account for directionality, influence, or causality between putatively interacting regions; it makes no assumptions about the nature of underlying pathways, their structure, nor anatomical connectivity. So while correlative methods provide a way to characterize neural functional networks by temporal coherence of inter-regional activation patterns, it yields neither an understanding of driving neural origins nor of the directionality of the observed network.

The next wave of imaging genetics: effective connectivity modeling

In contrast to functional connectivity approaches, effective connectivity analyses promise extended insight, referring explicitly to the influence that one neuronal system exerts over another, and may be used to better explain integration within a distributed neural system. Models employed in analyzing imaging data to uncover effective connectivity are based on regression models, or structural equation models, and these models may be linear or non-linear. Dynamic causal modeling (DCM) is a type of effective connectivity analysis that yields directional, pathway information and allows for a quantification of the influence of a given neural region over another.\(^5\)\(^7\)\(^8\) DCM analysis, introduced in 2003 for fMRI data, is a Bayesian framework for inferring hidden neuronal states from measurements of brain activity; it is a hypothesis-driven approach, requiring an a priori definition of a set of interconnected neural areas that mediate a given function of interest.\(^9\) DCMs are generative models of brain responses, which provide estimates of neurobiologically interpretable quantities including strength of synaptic connections among neuronal populations and their context-dependent modulation.\(^1\) Causality in DCM is based on control theory, ie, causal interactions among hidden state variables that are expressed by differential equations that describe how the present state of one neuronal population causes dynamics in another via synaptic connection, and how these interactions change under the influence of external perturbations (eg, experimental manipulations) or brain activity. DCM tests hypotheses about neuronal mechanisms, allowing one to specify a generative model of measured brain data, which is a probabilistic mapping from experimentally controlled manipulations to observed data, via neuronal dynamics.

DCM has begun to be applied to imaging genetics. Using a DCM approach, distributed circuits that putatively underlie working memory—prefrontal-parietal and prefrontal-striatal circuits—were identified in healthy, normal subjects, and \(COMT\), \(DRD2\), and \(AKT1\) functional variants were associated with the circuits.\(^4\) The goal of the study was to engage a hypothesis-driven strategy to study component dopamine signaling processes, both D2-mediated and non-D2-mediated aspects of dopamine signaling. The investigators developed a working memory task that allowed dissociation of working memory into
sub-processes, specifically maintenance of information and manipulation of information. In accordance with the DCM approach, models of prefrontal-subcortical-parietal networks were generated (each model’s nodes, connections, and inputs were generated) during working memory maintenance and manipulation events, and the optimal model with the highest group Bayes factor was determined. The best DCMs for maintenance were primarily prefrontal-parietal connections, while for manipulation, the circuit that best fit the data was a prefrontal-striatal network. These results fit remarkably well with data from nonhuman primates about subprocesses in working memory and the principal networks engaged. The cortical network engaged during maintenance is presumed to be a non-D2 dominated network, and indeed, only COMT showed association with activity in this network. In contrast, the cortical-striatal network is expected to be D2-dominated, and all three genes showed effects on this network. This study illustrates the greater fidelity of genetic association based on more realistic models of brain information processing.

In a study using nonlinear DCM, subjects at high familial risk of schizophrenia performed a sentence completion task, and the connection strength of the mediodorsal (MD) thalamus and inferior frontal gyrus (IFG) was investigated, revealing lower connection strength in the at-risk subjects. Bayesian Model Selection was used to compare the optimal bilinear and nonlinear models, and Bayesian Model Averaging was used to assess the connection strengths with the gating from the MD thalamus and the IFG, with nonlinear models providing better explanation of the data. In another study, dynamic causal models were applied to fMRI data to investigate how brain connectivity during an associative emotional learning task is affected by different PPP1R1B variants (DARPP32-encoding), in healthy subjects. A PPP1R1B variant was associated with increased connectivity between the inferior frontal gyrus (IFG), amygdala and parahippocampal gyrus (PHG), with directionality of the connectivity determined to be from the IFG to the PHG. In addition to emerging effective connectivity analyses by DCM, connectivity is being explored from a more systems-level, hierarchical perspective, using graph theory metrics to describe the structural and functional composition of neural circuits. In graph theory, the correlated activity across multiple, distributed preselected brain regions can be expressed in terms of a graph, having various quantitative parameters, such as nodes, hubs, edges, pathway length, and connectivity strength. The “hubs” of these networks correspond to the most highly interconnected neural regions, which typically map to the association cortices of the human brain. The strength of each node is defined as its average connectivity with all other nodes, and the graph’s size is defined by the number of nodes in the largest connected component; a larger graph size indicates fewer disconnected nodes.

Accumulating evidence suggests that the small-world topological properties of brain functional networks are altered in patients with schizophrenia. In one study, in 31 patients with schizophrenia compared with 31 healthy controls, functional connectivity between 90 cortical and subcortical regions was estimated by partial correlation analysis and thresholded to construct a set of undirected graphs. The healthy subjects demonstrated efficient small-world properties, whereas topological parameters of brain networks—strength and degree of connectivity—were decreased in patients with schizophrenia, especially in the prefrontal, parietal, and temporal lobes, consistent with a hypothesis of dysfunctional integration. In another study, in a sample of 203 patients with schizophrenia, compared with 259 healthy controls, multimodal network organization was noted to be abnormal, as measured by topological and distance metrics of anatomical network organization, abstracted from fMRI data. Patients with schizophrenia, compared with controls, demonstrated reduced hierarchy throughout the small-world regime, and increased connection distance in the multimodal cortical network. The loss of frontal hubs and the emergence of nonfrontal hubs was also noted, supporting the hypothesis of schizophrenia as a disconnection syndrome, impacting the efficiency of a frontally dominated hierarchical network of multimodal cortical connections. Though the impact of genetic variation on network topology based on graph analyses has not yet been reported, moderate levels of heritability have been found for brain graph topology measured in a twin study using EEG, suggesting that genetic variation may impact small-world organization and brain graph metrics.

The next wave of imaging genetics: polygenic risk

Just as imaging genetics will continue to incorporate increasingly sophisticated analytic methodologies, so too will imaging genetics evolve to incorporate increasingly
sophisticated models of genetic risk, reflective of the increasingly apparent polygenic complexity of psychiatric syndromes. Genome-wide association studies (GWAS) have indicated a highly significant polygenic component of schizophrenia risk, possibly involving up to thousands of common alleles of very small effect, at the population level. While early imaging genetics used intermediate phenotypes to assess the impact of single gene variants, recent studies have increasingly tended towards epistatic models of gene interaction. In 2007, Tan et al reported a two-way risk variant epistasis: the COMT-Val risk allele, associated with reduced prefrontal dopamine, and the GRM3 risk allele, related to suboptimal glutamatergic function, interacted to give disproportionately inefficient DLPFC activation in a working memory task. Further, the inefficiency was associated with reduced frontoparietal functional connectivity. Nicodemus et al reported the first 3-way interaction using neuroimaging genetics to assess the risk susceptibility of the \textit{NRG1} molecular pathway, finding epistasis between \textit{NRG1}, and its tyrosine kinase receptor \textit{ERBB4}, in a 3-way interaction with a variant of \textit{AKT1}. The statistical interaction was biologically validated by fMRI, in which healthy individuals carrying all three at-risk genotypes for \textit{NRG1}, \textit{ERBB4}, and \textit{AKT1} were disproportionately less efficient in DLPFC processing than any other combinations of one or two at-risk genotypes. Of note, lower-level interactions were not observed between \textit{NRG1}, \textit{ERBB4}, and \textit{AKT1}, suggesting that the interaction, and the \textit{NRG1} pathway, was necessary for the observed fMRI effect of inefficiency. Other reports of epistasis in neuroimaging genetics include association of variants with altered DLPFC activation, during working memory tasks including \textit{DISC1-CIT-NDEL1}, \textit{MTHFR-COMT}, and \textit{COMT-RGS4}. Imaging genetics is further evolving towards modeling increasing genetic complexity, by utilizing a polygenic risk score or propensity score of genetic risk for schizophrenia in fMRI studies. A range of options for constructing a polygenic score may be considered, selection of markers according to their \textit{P}-values in association studies, and different methods for weighting markers in the score. Only a handful of studies utilizing a polygenic risk score have been reported to date, using both functional and structural neuroimaging, and for multiple psychiatric syndromes. Walton et al calculated a genetic risk score for schizophrenia, the additive effect of 41 SNPS from 34 putative risk genes, and found a positive relationship between the genetic risk score and left DLPFC inefficiency during a working memory task. Holmes et al reported a structural anatomic association with polygenic risk for Major Depressive Disorder (MDD) in a sample of 1050 healthy young adults with no history of psychiatric illness. Using risk scores derived from large MDD GWAS analyses, an MDD polygenic score was found to be associated with reduced cortical thickness in the left medial prefrontal cortex, a structural variation that is believed to influence vulnerability to MDD. In a third study, increasing polygenic risk allele load for bipolar affective disorder (BPAD) was associated with increased activation in limbic regions previously implicated in BPAD, including the anterior cingulate cortex and amygdala during a verbal fluency task. So, while a few early imaging genetics studies have employed the polygenic risk score, use of the polygenic score approach remains to be assessed and validated in larger-scale, more robust studies, with an explicit focus on schizophrenia and with various models of the risk score calculation possible.

\textbf{Conclusion}

As highlighted in this review, initial methodological and conceptual advances in functional neuroimaging launched the epoch of imaging genetics. Since then, development of genetic vulnerability maps of the brain, identifying neuroimaging intermediate phenotypes of schizophrenia and the risk variants associated with them, have become a major research industry. While imaging genetics to date has led to an increased understanding of schizophrenia pathophysiology and potential sites of pharmacologic intervention, a new wave of imaging genetics is fueled by even further methodological and conceptual advances. Effective connectivity modeling promises to offer causal and directional insight into brain networks and circuitry, and polygenic risk modeling promises to incorporate genetic models reflective of the polygenic complexity of the schizophrenia syndrome.
Neuroimágenes funcionales y esquizofrenia: una mirada hacia el modelo de conectividad efectiva y el riesgo poligénico

Se revisan las tendencias más importantes en imágenes y genética aplicadas a la investigación en esquizofrenia y se discuten algunas perspectivas a futuro en este campo. Gran cantidad de estudios de imágenes y genética han investigado el impacto de la variación genética en la función cerebral desde que apareció el paradigma de un fenotipo intermedio de neuroimágenes para la esquizofrenia. Inicialmente se postuló que los efectos de los genes susceptibles para la esquizofrenia tendrían una mayor penetración a nivel de los fenotipos intermedios de neuroimágenes con base biológica que a nivel de un síndrome psiquiátrico complejo y fenotípicamente heterogéneo. Los resultados de muchos estudios apoyan esta hipótesis y la mayoría de ellos muestra variantes genéticas únicas que se asocian con cambios en la actividad de regiones cerebrales localizadas, como se puede determinar a través de la selección de tareas cognitivas controladas. A partir de estos estudios básicos, el análisis de neuroimágenes funcionales de los fenotipos intermedios ha progresado hacia modelos de disfunciones cerebrales más complejos y realistas, incorporando modelos de conectividad funcional y efectiva, que incluyen las modalidades de interacción psicofisiológica, el modelo causal dinámico y las mediciones de la teoría de los grafos. Los enfoques de asociación genética aplicados a las imágenes y genética han progresado hacia efectos multivariados más sofisticados, incluyendo la incorporación de interacciones epistáticas de dos o tres vías, y más recientemente modelos de riesgo poligénico. Las imágenes y genética constituyen una estrategia única y poderosa para la comprensión de los mecanismos neurales de riesgo genético de trastornos complejos del sistema nervioso central a nivel del cerebro humano.

Schizophrénie et neuroimagerie fonctionnelle : point de vue sur la modélisation de la connectivité effective et le risque polygénique

Nous examinons l’évolution déterminante de la neuro-imagerie génétique appliquée à la recherche sur la schizophrénie, puis nous analysons les futures possibilités de ce domaine. Une pléthore d’études associant la neuro-imagerie et la génétique a recherché l’influence de la variation génétique sur la fonction cérébrale, depuis l’émergence initiale d’un paradigme de phénotype intermédiaire de schizophrénie en neuro-imagerie. Il a d’abord été postulé que les effets des gènes de susceptibilité à la schizophrénie seraient plus pénétrants au niveau des phénomènes intermédiaires de neuro-imagerie basés sur la biologie, qu’au niveau d’un syndrome psychiatrique complexe et phénotypiquement hétérogène. Les résultats de plusieurs études soutiennent cette hypothèse, la plupart mettant en évidence des variants génétiques uniques associés à des changements de l’activité de régions cérébrales localisées, déterminés par des tâches cognitives contrôlées définies. À partir de ces études fondamentales, l’analyse fonctionnelle de la neuro-imagerie des phénomènes intermédiaires a évolué vers des modèles plus complexes et réels de dysfonction cérébrale, comportant des modèles de connectivité effective et fonctionnelle, comme les modalités d’interaction psychophysiologique, la modélisation causale dynamique et les méthodes théoriques graphiques. Les méthodes d’association génétique appliquées à la neuro-imagerie génétique ont aussi progressé vers des effets multivariés plus sophistiqués, englobant des interactions épistatiques à 2 et 3 voies et plus récemment des modèles de risque polygénique. La neuro-imagerie génétique est une méthode puissante et originale de compréhension des mécanismes neuroaux du risque génétique pour les troubles complexes du SNC chez l’être humain.

REFERENCES
1. Weinberger DR, Mattay V, Callicott J, et al. fMRI applications in schizophrenia research. Neuroimage. 1996;4:S118-S126.
2. Bookheimer SY, Strojwas MH, Cohen MS, et al. Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med. 2000;343:450-456.
3. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A. 2001;98:6917-6922.
4. Egan MF, Weinberger DR. Neurobiology of schizophrenia. Curr Opin Neurobiol. 1997;7:701-707.
5. Castelli WP, Anderson K, Wilson PW, Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol. 1992;2:23-28.
6. O’Connor DT, Insel PA, Ziegler MG, et al. Heredity and the autonomic nervous system in human hypertension. Curr Hypertens Rep. 2000;2:16-22.
7. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etiology and strategic intentions. Am J Psychiatry. 2003;160:636-645.
8. Tan HY, Callicott JH, Weinberger DR. Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer? Mol Psychiatry. 2008;13:233-238.
9. Cannon TD, Zorrilla LE, Shtasel D, et al. Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry. 1994;51:651-661.
10. Goldberg TE, Torrey EF, Gold JM, et al. Genetic risk of neuropsychological impairment in schizophrenia: a study of monozygotic twins discordant and concordant for the disorder. Schizophr Res. 1995;17:77-84.
11. Touloumpoulou T, Picchioni M, Rijsdijk F, et al. Substantial genetic overlap between neurocognition and schizophrenia: genetic modeling in twin samples. Arch Gen Psychiatry. 2007;64:1348-1355.
12. Egan MF, Goldberg TE, Gschaidle T, et al. Relative risk for cognitive impairment in siblings of patients with schizophrenia. Biol Psychiatry. 2001;50:98-107.
13. Callicott JH, Egan MF, Mattay VS, et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am J Psychiatry. 2003;160:709-719.
14. Rasetti R, Weinberger DR. Intermediate phenotypes in psychiatric disorders. Curr Opin Genet Dev. 2011;21:340-348.
15. Honea R, Crew TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry. 2005;162:2233-2245.
16. Shenton ME, Dickey CC, Frumin M, McCauley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001;49:1-52.
17. Wright IC, Rabe-Hesketh S, Woodruff PW, David AS, Murray RM, Bullmore ET. Meta-analysis of regional brain volumes in schizophrenia. Am J Psychiatry. 2000;157:16-25.
18. Weinberger DR, McCabe RR. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 2002;59:553-568.
19. Hajnal JV, Saeed N, Gatridge A, et al. Detection of subtle brain changes using subvoxel registration and subtraction of serial MR images. J Comput Assist Tomogr. 1995;19:677-691.
20. Swayze VW 2nd, Andersen A, Arndt S, et al. Reversibility of brain tissue loss in anorexia nervosa assessed with a computerized Talairach 3-D proportional grid. Psychol Med. 1996;26:381-390.
21. Schroth G, Naegele T, Kloos U, Mann K, Petersen D. Reversible brain shrinkage in abstinent alcoholics, measured by MRI. Neurology. 1988;30:385-389.
22. Denton ER, Holden M, Christ E, et al. The identification of cerebral volume changes in treatment-naive hormone deficient adults using serial 3D MR image processing. J Comput Assist Tomogr. 2000;24:139-145.
23. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet. 2000;356:1241-1242.
24. Scheepers FE, de Wied CC, Hulshoff Pol HE, et al. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology. 2001;24:47-54.
25. Corson PW, Nopoulos P, Miller DR, Arndt S, Andreassen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry. 1999;156:1200-1204.
26. Honea RA, Meyer-Lindenberg A, Hobbs KB, et al. Is gray matter volume an intermediate phenotype for schizophrenia? A voxel-based morphometry study of patients with schizophrenia and their healthy siblings. Biol Psychiatry. 2008;63:465-474.
27. Owens SF, Picchioni MM, Ettinger U, et al. Prefrontal deviations in function but not volume are putative endophenotypes for schizophrenia. Brain. 2012;135:2231-2244.
28. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A. 2003;100:253-258.
29. Broyd SJ, Demanuele C, Debener S, Helps SK, James CJ, Sonuga-Barke EJ. Default-mode brain dysfunction in mental disorders: a systematic review. Neurosci Biobehav Rev. 2009;33:279-296.
30. van den Heuvel MP, Hulshoff Pol HE. Exploring the brain network: a review on resting-state fMRI functional connectivity. Eur Neuropsychopharmacol. 2010;20:519-534.
31. Samartzi L, Dima D, Fasar-Poli P, Kyriakopoulos M. White matter alterations in early stages of schizophrenia: a systematic review of diffusion tensor imaging studies. J Neuroimag. 2013;doi: 10.1111/j.1552-6569. In press.
32. Whitford TJ, Kubicki M, Shenton ME. Diffusion tensor imaging, structural connectivity, and schizophrenia. Schizophr Res Treatment. 2011;doi: 10.1155/2011/709523. In press.
33. Buckner RL, Krienen FM, Yeo BT. Opportunities and limitations of intrinsic functional connectivity MRI. Nat Neurosci. 2013;16:832-837.
34. Jones DK, Knösche TR, Turner R, White matter integrity, fiber count, and other fallacies: the do’s and don’ts of diffusion MRI. Neuroimage. 2013;73:239-254.
35. Logothetis NK. What we can do and what we cannot do with fMRI. Nature. 2008;453:869-878.
36. Douglas RJ, Martin KA. Neuronal circuits of the neocortex. Annu Rev Neurosci. 2004;27:419-451.
37. Brunel N, Wang XY. Effects of neuro modulation in a cortical network model of object working memory dominated by recurrent inhibition. J Comput Neurosci. 2001;11:63-85.
38. Rockel AJ, Horsn RW, Powell TP. The basic uniformity in structure of the neocortex. Brain. 1980;103:221-244.
39. Egan MF, Straub RE, Goldberg TE, et al. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A. 2004;101:12604-12609.
40. Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science. 2002;297:400-407.
41. Rasetti R, Weinberger DR. Intermediate phenotypes in psychiatric disorders. Curr Opin Genet Dev. 2011;21:340-348.
42. Sambataro F, Mattay VS, Thurin K, et al. Altered cerebral response during cognitive control: a potential indicator of genetic liability for schizophrenia. Neuropsychopharmacology. 2013;38:846-853.
43. Di Giorgio A, Gelaio B, Caforio G, et al. Evidence that hippocampal-parahippocampal dysfunction is related to genetic risk for schizophrenia. Psychol Med. 2012;1-11.
44. Friston KJ. Functional and effective connectivity in neuroimaging: a synthesis. Hum Brain Mapp. 1994;2:56-78.
45. Meyer-Lindenberg, A, Bullmore E. Functional brain imaging in schizophrenia. In: Schizophrenia. Third Ed, Oxford, UK: Blackwell Publishing Ltd; 2011:334-353.
46. Honey GD, Bullmore ET, Sharma T. De-coupling of cognitive performance and cerebral functional response during working memory in schizophrenia. Schizophr Res. 2002;53:45-56.
47. Anticevic A, Repovs G, Krystal JH, Barch DM. A broken filter: prefrontal functional connectivity abnormalities in schizophrenia during working memory interference. Schizophr Res. 2012;141:8-14.
48. Wolf DH, Gur RC, Valdez JN, et al. Alterations of frontal-temporal connectivity during word encoding in schizophrenia. Psychiatry Res. 2007;154:221-232.
49. Wolf RC, Vasic N, Sambataro F, et al. Temporally anticorrelated brain networks during working memory performance reveal abarent prefrontal and hippocampal connectivity in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1464-1473.
50. Tan HY, Chen Q, Goldberg TE, et al. Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci. 2007;27:13393-13401.
51. Kempt L, Nicodemus KK, Kolachana B, et al. Functional polymorphisms in PRODH are associated with risk and protection for schizophrenia and fronto-striatal structure and function. PLoS Genet. 2008;4:e1000252.
52. Meyer-Lindenberg A, Straub RE, Lipska BK, et al. Genetic evidence implicating DARPP-32 in human frontotstriatal structure, function, and cognition. J Clin Invest. 2007;117:672-682.
53. Buckholtz JW, Meyer-Lindenberg A, Honea RA, et al. Allelic variation in RGS4 impacts functional and structural connectivity in the human brain. J Neurosci. 2007;27:1584-1593.
During associative emotional learning.

Variation of the gene coding for DARPP-32 (PPP1R1B) and brain connectivity in schizophrenia. *Annu Rev Clin Psychol*. 2011;7:113–140.

Tost H, Bilek E, Meyer-Lindenberg A. Brain connectivity in psychiatric imaging genetics. *Neuroimage*. 2012; 62:2250-2260.

Friston KJ, Harrison L, Penny W. Dynamic causal modelling. *Neuroimage*. 2003;19:1273-1302.

Stephan KE, Penny WD, Moran RJ, den Ouden HE, Daunizeau J, Friston KJ. Ten simple rules for dynamic causal modeling. *Neuroimage*. 2010;49:3099-3109.

Tan HY, Chen AG, Kolachana B, et al. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. *Brain*. 2012;135:1436-1445.

Dauvermann MR, Whalley HC, Bassett DS, Nelson BG, Mueller BA, Camchong J, Lim KO. Altered resting-state complexity in schizophrenia. *Neuroimage*. 2012;59:2196-2207.

Bassett DS, Bullmore E, Verchinski BA, et al. Hierarchical organization of human cortical networks in health and schizophrenia. *J Neurosci*. 2008;28:9239-9248.

Smit DJ, Stam CJ, Posthuma D, Boomsma DI, de Geus EJ. Heritability of “small-world” networks in the brain: a graph theoretical analysis of resting-state EEG functional connectivity. *Hum Brain Mapp*. 2008;29:1368–1378.

International Schizophrenia Consortium: Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460:748-752.

Tan HY, Chen Q, Sust S, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. *Proc Natl Acad Sci U S A*. 2007;104:12536–12541.

Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with NR81, ER884, and AKT1 epistasis via functional neuroimaging in healthy controls. *Arch Gen Psychiatry*. 2010;67:991-1001.

Nicodemus KK, Callicott JH, Higley RG, et al. Evidence of statistical epistasis between DISC1, C1R and NDE1 impacting risk for schizophrenia: biological validation with functional neuroimaging. *Hum Genet*. 2010;127:441-452.

Roffman JL, Weiss AP, Deckersbach T, et al. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2008;147B:990–995.

Buckholtz JW, Sust S, Tan HY, et al. fMRI evidence for functional epistasis between COMT and RG54. *Mol Psychiatry*. 2007;12:893-895,885.

Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLOS Genet*. 2013;9:e1003348.

Walton E, Turner J, Gollub RL, et al. Cumulative genetic risk and prefrontal activity in patients with schizophrenia. *Schizophr Bull*. 2013;39:703-711.

Holmes AJ, Lee PH, Hollinshead MO, et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. *J Neurosci*. 2012;32:18087-18100.

Whalley HC, Papmeyer M, Sprooten E, et al. The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI. *Transl Psychiatry*. 2012;2:e130.

54. Paulus FM, Bedenbender J, Krach S, et al. Association of rs1006737 in CACNA1C with alterations in prefrontal activation and fronto-hippocampal connectivity. *Hum Brain Mapp*. 2013;34:304-313.

55. Friston KJ, Buechel C, Fink GR, Morris J, Rolls E, Dolan RJ. Psychophysiological and modular interactions in neuroimaging. *NeuroImage*. 1997;6:218–229.

56. Rasetti R, Sambataro F, Chen Q, Callicott JH, Mattay VS, Weinberger DR. Altered cortical network dynamics: a potential intermediate phenotype for schizophrenia and association with ZNF804A. *Arch Gen Psychiatry*. 2011;68:1207-1217.

57. K.J. Friston, B. Li, J. Daunizeau, K.E. Stephan. Network discovery with DCM. *NeuroImage*. 2011; 56: 1202–1221.

58. Tost H, Bilek E, Meyer-Lindenberg A. Brain connectivity in psychiatric imaging genetics. *Neuroimage*. 2012; 62:2250-2260.

59. Friston KJ, Harrison L, Penny W. Dynamic causal modelling. *Neuroimage*. 2003;19:1273-1302.

60. Stephan KE, Penny WD, Moran RJ, den Ouden HE, Daunizeau J, Friston KJ. Ten simple rules for dynamic causal modeling. *Neuroimage*. 2010;49:3099-3109.

61. Tan HY, Chen AG, Kolachana B, et al. Effective connectivity of AKT1-mediated dopaminergic working memory networks and pharmacogenetics of anti-dopaminergic treatment. *Brain*. 2012;135:1436-1445.

62. Dauvermann MR, Whalley HC, Romaniuk L, et al. The application of nonlinear Dynamic Causal Modelling for fMRI in subjects at high genetic risk of schizophrenia. *Neuroimage*. 2013;72:16-29.

63. Curcić-Blake B, Swart M, Ter Horst GJ, Langers DR, Kema IP, Aleman A. Variation of the gene coding for DARPP-32 (PPP1R1B) and brain connectivity during associative emotional learning. *Neuroimage*. 2012;59:1540-1550.

64. Achar S, Salvador R, Whitther B, Suckling J, Bullmore E. A resilient, low-frequency, small-world human brain functional network with highly connected association cortical hubs. *J Neurosci*. 2006;26:63-72.

65. Bullmore E, Bassett, D. Brain graphs: graphical models of the human brain connectome. *Annu Rev Clin Psychol*. 2011;7:113–140.

66. Bassett DS, Nelson BG, Mueller BA, Camchong J, Lim KO. Altered resting-state complexity in schizophrenia. *Neuroimage*. 2012;59:2196-2207.

67. Bullmore ET, Bassett DS. Brain graphs: graphical models of the human brain connectome. *Annu Rev Clin Psychol*. 2011;7:113-140.

68. Liu Y, Liang M, Zhou Y, et al. Disrupted small-world networks in schizophrenia. *Brain*. 2008;131(Pt 4):945-961.

69. Bassett DS, Bullmore E, Verchinski BA, et al. Hierarchical organization of human cortical networks in health and schizophrenia. *J Neurosci*. 2008;28:9239-9248.

70. Smit DJ, Stam CJ, Posthuma D, Boomsma DI, de Geus EJ. Heritability of “small-world” networks in the brain: a graph theoretical analysis of resting-state EEG functional connectivity. *Hum Brain Mapp*. 2008;29:1368–1378.

71. International Schizophrenia Consortium: Purcell SM, Wray NR, Stone JL, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. *Nature*. 2009;460:748-752.

72. Tan HY, Chen Q, Sust S, et al. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. *Proc Natl Acad Sci U S A*. 2007;104:12536–12541.

73. Nicodemus KK, Law AJ, Radulescu E, et al. Biological validation of increased schizophrenia risk with NR1G1, ER884, and AKT1 epistasis via functional neuroimaging in healthy controls. *Arch Gen Psychiatry*. 2010;67:991-1001.

74. Nicodemus KK, Callicott JH, Higley RG, et al. Evidence of statistical epistasis between DISC1, C1R and NDE1 impacting risk for schizophrenia: biological validation with functional neuroimaging. *Hum Genet*. 2010;127:441-452.

75. Roffman JL, Weiss AP, Deckersbach T, et al. Interactive effects of COMT Val108/158Met and MTHFR C677T on executive function in schizophrenia. *Am J Med Genet B Neuropsychiatr Genet*. 2008;147B:990–995.

76. Buckholtz JW, Sust S, Tan HY, et al. fMRI evidence for functional epistasis between COMT and RG54. *Mol Psychiatry*. 2007;12:893-895,885.

77. Dudbridge, F. Power and predictive accuracy of polygenic risk scores. *PLOS Genet*. 2013;9:e1003348.

78. Walton E, Turner J, Gollub RL, et al. Cumulative genetic risk and prefrontal activity in patients with schizophrenia. *Schizophr Bull*. 2013;39:703-711.

79. Holmes AJ, Lee PH, Hollinshead MO, et al. Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. *J Neurosci*. 2012;32:18087-18100.

80. Whalley HC, Papmeyer M, Sprooten E, et al. The influence of polygenic risk for bipolar disorder on neural activation assessed using fMRI. *Transl Psychiatry*. 2012;2:e130.